MDMA versus MDNR Listing: Two Entry Tiers for Saudi Market Access

1. Key takeaways

Saudi market access is not a single entrance but a two-tier system. The first tier is the full MDMA (Medical Device Marketing Authorization), covering the vast majority of devices; the second tier is the MDNR (Medical Device National Registry) listing, accepting only the lowest-risk slice of Class A devices. Whether a product can use the second tier depends on the conjunction of 6 conditions: Class A, non-sterile, no measuring function, not a reusable surgical instrument, not an IVD, not an innovative device. Per third-party public sources, MDNR review takes about 4 working days with a 3-year validity (practical estimate); the SFDA’s current notices and the GHAD portal output prevail. Fix the classification first, then choose the pathway — Class A is necessary but not sufficient for MDNR. Regulatory information verified as of 29 October 2026.

• Full MDMA covers most devices; MDNR listing is reserved for the lowest-risk slice of Class A.
• Six cumulative conditions gate the MDNR lane; a single failure forces the product back into the MDMA channel.
• The MDNR figures (about 4 working days; 3-year validity) are third-party retellings (practical estimate).
• Class A is necessary but not sufficient for MDNR; classify before choosing the pathway.

2. Legal basis

The following instruments define the two-tier entry system, the registration obligations behind it and the electronic submission channel. Third-party retellings are marked as practical estimates together with their verification actions.

3. Expert insights

1. Why the SFDA carved out a separate lane for ultra-low-risk devices

Regulatory resources are never unlimited. If a tongue depressor and an implantable cardioverter defibrillator went through the same review process, they would consume the same reviewers’ time. The MDNR’s institutional meaning lies exactly here: the lowest-technology, mildest-consequence products enter a registry lane, so the device’s basic facts (name, model, manufacturer, class) enter the national ledger without an independent technical file review. Structurally this sits close to China NMPA’s Class I filing route, the US FDA’s Class I exemptions, and the self-declaration route for some Class I devices under the EU MDR. The difference is that Saudi Arabia has not abandoned the external licence-holder role — Law M/54 Article 1 defines the authorised representative as a legal person located within Saudi Arabia, authorised in writing by the foreign manufacturer to represent it under the law and its regulations. Even under the MDNR, foreign manufacturers in practice still need a Saudi legal entity to interface with the authority.

2. The real screening function of the six negative conditions

The MDNR conditions are not six adjectives listed at random; each corresponds to a class of risk that would otherwise drag in additional technical review. Non-sterile, because sterility assurance must rest on sterilization validation and packaging verification. No measuring function, because metrological performance requires independent traceability evidence. Not a reusable surgical instrument, because reuse implicates cleaning, disinfection, sterilization and the reprocessing procedures defined in Law M/54 Article 1. Not an IVD, because the technical file structure of in vitro diagnostics differs entirely from that of devices (Annex (3) and Annex (4) are separate). Not an innovative device, because Article 1 defines it as one novel in technology, intended use or performance, not previously marketed locally or internationally, leaving no reference comparator. The six conditions together guarantee that the MDNR queue requires no further questions.

3. Choosing the wrong pathway costs a process restart, not a document top-up

Once the pathway is locked in GHAD, what follows are different fee categories, document lists and intake rhythms. When a product filed under MDNR is pushed back to the MDMA channel, it usually cannot be fixed by adding two waiver letters; the application fee billed by risk class (rates in article 38 of this series) must be paid again and the review clock restarts. Conversely, a product that could have used MDNR but went through MDMA pays one round of cost for nothing. Lock the pathway together with the classification at the classification stage, not at submission. If the A/B/C/D classification rules and common misjudgements are still unclear, first read https://www.grzan.cn/regulations/saudi/sfda-risk-classification-abcd-06 ; the GHAD entrance’s institutional meaning is covered in https://www.grzan.cn/regulations/saudi/ghad-electronic-portal-10 .

4. Practical recommendations

• Complete the classification determination in e-GHAD before starting the pathway assessment; do not infer the Saudi class backwards from another country’s registration number or risk level.
• Check each of the six MDNR conditions in its negative form and anchor every not to an original document: non-sterile needs a sterile-status statement; no measuring function needs the technical specification sheet.
• An ISO 13485:2016 certificate scope change (a new product line or site) can retroactively affect whether the chosen pathway can be maintained.
• MDNR review time and validity are third-party retellings; do not hard-code a 3-year term in the ledger — write that the dates on the certificate or listing record prevail.
• The appointed AR must first obtain the relevant qualification under MDS-REQ 9; an authorisation letter issued unilaterally by the foreign manufacturer is not enough to start a filing.
• Companies planning product-line extensions should reserve bundling space for future models at the first pathway decision, avoiding a fresh application for every new SKU.
• If any product might later become a sterile version, evaluate the MDMA route directly at initial registration to avoid cross-pathway migration. In pathway assessments GRZAN lists in reverse the three stories that would force an upgrade — a sterility requirement, a measuring function, a new indication — and prepares for MDMA if any could land within two years.

5. Verification checklist

• □ A formal classification decision for the target product has been obtained in GHAD / e-GHAD, concluding Class A
• □ Non-sterile status, absence of a measuring function, non-reusability, non-IVD and non-innovative status have each been confirmed
• □ Current SFDA notices confirm the MDNR lane is still open and not merged into a new MDMA process
• □ AR qualification (under MDS-REQ 9) and the authorisation letter have completed the signing, notarisation and legalisation chain
• □ The ISO 13485:2016 certificate was issued by an SFDA-recognised CAB and covers the filed products’ activities
• □ Model names, GMDN codes and Saudi-DI data in GHAD are consistent
• □ The ledger states the issuance and expiry dates on the carrier prevail, with no fixed term hard-coded
• □ The fee budget is prepared by class band, includes 15% VAT and follows the GHAD billing

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Saudi Arabian market. Our team manages SFDA MDMA applications across classes, prepares reference-approval dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzan.com